T
Terapet
Next-generation imaging solutions for nuclear medicine, including proton therapy and precision medicine
About Terapet
Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qualγscan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Satigny, Switzerland
- Sector
- Health Tech & Medtech
Knowledge graph
News
More headlines
Open roles
Terapet in the Satigny ecosystem
The Terapet office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Nina Capital
EFI
FONGIT
Innosuisse
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Terapet on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Terapet on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.